Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02783170 · ClinicalTrials.gov registry record · Phase 4
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
A Phase 4 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 4
- Development phase
- 81
- Enrollment target
NCT02783170 is a Phase 4 study that has completed, run by Duke University. The registered enrollment target is 81 participants.
The verdict
NCT02783170, a Phase 4 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 81 participants
- Enrollment target
Study Summary
This is a pilot, prospective, randomized, open-label clinical trial. During the study, pregnant women will be randomized (1:1) to receive co-administration of a single intramuscular (IM) 0.5 mL dose of US-licensed inactivated influenza vaccine (IIV) and a single intramuscular (IM) 0.5 mL dose of US-licensed Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap) or sequential administration of the vaccines (IIV followed by Tdap \~ 21 days later). Vaccines will be administered by licensed study personnel. Prior Tdap/Td/TT and influenza vaccine history will be verified by medical record review when possible. Injection-site (local) and systemic reaction data will be assessed on vaccination day and during the 7 days following vaccination using either identical web-based or paper diaries, depending on study participant preference. Maternal serum samples will be collected for antibody titers relevant to the Tdap and Influenza at time points that include: prior to vaccination(s), \~21 days post vaccination(s), and at delivery. Additionally, cord blood serum will be analyzed for the same antibody titers. Pregnant women will be followed with comprehensive obstetric and neonatal outcomes obtained from medical record review.
Interventions
- BIOLOGICAL Tetanus, Diphtheria, and Pertussis Vaccine
- BIOLOGICAL 2016-2017 Quadrivalent Inactivated Influenza Vaccine
- BIOLOGICAL 2017-2018 Quadrivalent Inactivated Influenza Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2016-09 |
| Est. Completion | 2018-05-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02783170
The ClinicalTrials.gov registry entry for NCT02783170 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tetanus, Diphtheria, and Pertussis Vaccine is the first listed.
NCT02783170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02783170 about?
NCT02783170 is a clinical study titled "Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women". This is a pilot, prospective, randomized, open-label clinical trial. During the study, pregnant women will be randomized (1:1) to receive co-administration of a single intramuscular (IM) 0.5 mL dose of US-licensed inactivated influenza vaccine (IIV) and a single intramuscular (IM) 0.5 mL dose of US-...
What is the current status of trial NCT02783170?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 81 participants. The study started on 2016-09. Estimated completion is 2018-05-10.
What interventions are being tested in trial NCT02783170?
The interventions under investigation include: Tetanus, Diphtheria, and Pertussis Vaccine (BIOLOGICAL), 2016-2017 Quadrivalent Inactivated Influenza Vaccine (BIOLOGICAL), 2017-2018 Quadrivalent Inactivated Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02783170?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.